Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SENECA: CAPTEM vs FOLFIRI as second-line therapy in neuroendocrine carcinomas
2016-000767-17Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine, temozolomide, irinotecan, levoleucovorin and fluorouracil in neuroendocrine carcinoma (NEC) (2 arms), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Disease control rate and Safety. Started Sep 2018; status: terminated.
02
Drugs
capecitabinetemozolomideirinotecanlevoleucovorinfluorouracil
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2016-000767-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000767-17.